ReviewCurrent neuropharmacology2018
Resilience Dysregulation in Major Depressive Disorder: Focus on Glutamatergic Imbalance and Microglial Activation.
Review in Current neuropharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 46 citations in OpenAlex.
- The effects of an 8-week Taekwondo exercise intervention on inhibitory control in university students with depressive symptoms demonstrated the following-evidence from behavior and ERPs.BMC psychiatry · 2025Trial
- The Function of Microglia in Cognitive Impairment Influenced by Sleep Deprivation.Cellular and molecular neurobiology · 2026Review
- Circadian syndrome, not metabolic syndrome, is a significant predictor of mild cognitive impairment in middle-aged and older adults - The CHARLS survey during 2015-2018.BMC public health · 2026Article
- Dapagliflozin Reverses LPS-Induced Depressive-Like Behavior in Mice via Modulation of Glutamate and NF-κB.Genes, brain, and behavior · 2025Article
- Inhibition of microglial glutaminase alleviates chronic stress-induced neurobehavioral and cognitive deficits.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2025Article
- COVID-19, Anxiety, and Body Mass Index Increase Leptin Levels: a Cross-sectional Multicentric Study.Molecular neurobiology · 2024Article
- Effect of a multi-strain probiotic mixture consumption on anxiety and depression symptoms induced in adult mice by postnatal maternal separation.Microbiome · 2024Article
- Antidepressant Drugs for Seizures and Epilepsy: Where do we Stand?Current neuropharmacology · 2023Review
- The Wither or Thrive Model of Resilience: an Integrative Framework of Dynamic Vulnerability and Resilience in the Face of Repeated Stressors During the COVID-19 Pandemic.Adversity and resilience science · 2022Review
- Environmental enrichment improves lifelong persistent behavioral and epigenetic changes induced by early-life stress.Journal of psychiatric research · 2021Article
- The role of microglia in chronic pain and depression: innocent bystander or culprit?Psychopharmacology · 2021Review
- Motor Stereotypic Behavior Was Associated With Immune Response in Macaques: Insight From Transcriptome and Gut Microbiota Analysis.Frontiers in microbiology · 2021Article
- Mechanisms of the Rapid Effects of Ketamine on Depression and Sleep Disturbances: A Narrative Review.Frontiers in pharmacology · 2021Review
- Cannabidiol: A Potential New Alternative for the Treatment of Anxiety, Depression, and Psychotic Disorders.Biomolecules · 2020Review
- The Contribution of Rat Studies to Current Knowledge of Major Depressive Disorder: Results From Citation Analysis.Frontiers in psychology · 2020Article
- Mechanisms of Panax ginseng action as an antidepressant.Cell proliferation · 2019Review
- Glial gene networks associated with alcohol dependence.Scientific reports · 2019Article
- JHU-083 selectively blocks glutaminase activity in brain CD11bNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMany studies have been shown an important role of glutamatergic system as well microglial activation in the pathophysiology of major depressive disorder (MDD). In humans most resistant to the development of psychiatric disorders, including MDD, are observed a greater degree of resilience resulting from stress. Less resilience is associated with neuroendocrine and neuroinflammatory markers, as well as with glutamatergic system dysregulation. Thus, this review we highlighted findings from literature identifying the function of glutamatergic system, microglial activation and inflammation in resilience.
methodsWe conducted a review of computerized databases from 1970 to 2017.
resultsThere is an association between microglial activation and glutamatergic system activation with stress vulnerability and resilience.
conclusionsGlutamate neurotransmission, including neurotransmitter synthesis, signalling, and glutamate receptor functions and expression all seem to be involved with both stress vulnerability and resilience. Moreover, inflammation and microglial activation mediate individual differences in resilience and the risk of stress-induced MDD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.